420 related articles for article (PubMed ID: 9182472)
1. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
Giugliano D; Acampora R; Marfella R; De Rosa N; Ziccardi P; Ragone R; De Angelis L; D'Onofrio F
Ann Intern Med; 1997 Jun; 126(12):955-9. PubMed ID: 9182472
[TBL] [Abstract][Full Text] [Related]
2. Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.
Eriksson JW; Jansson PA; Foley K; Lithell H
J Hypertens; 1996 Dec; 14(12):1469-75. PubMed ID: 8986932
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
Ruilope LM
Am J Hypertens; 1994 Feb; 7(2):129-36. PubMed ID: 7910028
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol.
Marchi F; Ciriello G
Adv Ther; 1995; 12(4):212-21. PubMed ID: 10155349
[TBL] [Abstract][Full Text] [Related]
5. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.
Bell DS; Bakris GL; McGill JB
Diabetes Obes Metab; 2009 Mar; 11(3):234-8. PubMed ID: 18564334
[TBL] [Abstract][Full Text] [Related]
6. Current concepts of pharmacotherapy in hypertension. Carvedilol: new considerations for its use in the diabetic patient with hypertension.
Sica DA
J Clin Hypertens (Greenwich); 2005 Jan; 7(1):59-64. PubMed ID: 15655391
[No Abstract] [Full Text] [Related]
7. How safe is carvedilol in NIDDM patients with hypertension?
Choudhury D; Misra A
Natl Med J India; 1998; 11(3):130-1. PubMed ID: 9707705
[No Abstract] [Full Text] [Related]
8. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
Bakris GL; Fonseca V; Katholi RE; McGill JB; Messerli FH; Phillips RA; Raskin P; Wright JT; Oakes R; Lukas MA; Anderson KM; Bell DS;
JAMA; 2004 Nov; 292(18):2227-36. PubMed ID: 15536109
[TBL] [Abstract][Full Text] [Related]
9. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension.
Giugliano D; Marfella R; Acampora R; Giunta R; Coppola L; D'Onofrio F
Diabetes Care; 1998 Apr; 21(4):631-6. PubMed ID: 9571355
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes.
Fogari R; Zoppi A; Lazzari P; Mugellini A; Lusardi P; Preti P; Van Nueten L; Vertommen C
J Hum Hypertens; 1997 Nov; 11(11):753-7. PubMed ID: 9416986
[TBL] [Abstract][Full Text] [Related]
11. The effect of carvedilol on metabolic parameters in patients with metabolic syndrome.
Uzunlulu M; Oguz A; Yorulmaz E
Int Heart J; 2006 May; 47(3):421-30. PubMed ID: 16823248
[TBL] [Abstract][Full Text] [Related]
12. A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group.
Young PH
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S82-5. PubMed ID: 1378155
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of carvedilol in hypertensive patients.
Lithell H; Andersson PE
Eur J Clin Pharmacol; 1997; 52(1):13-7. PubMed ID: 9143861
[TBL] [Abstract][Full Text] [Related]
14. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Curb JD; Pressel SL; Cutler JA; Savage PJ; Applegate WB; Black H; Camel G; Davis BR; Frost PH; Gonzalez N; Guthrie G; Oberman A; Rutan GH; Stamler J
JAMA; 1996 Dec; 276(23):1886-92. PubMed ID: 8968014
[TBL] [Abstract][Full Text] [Related]
15. Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension.
Bönner G; Schmieder R; Chrosch R; Weidinger G
Cardiovasc Drugs Ther; 1997 Mar; 11(1):21-6. PubMed ID: 9140673
[TBL] [Abstract][Full Text] [Related]
16. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial.
Bakris GL; Bell DS; Fonseca V; Katholi R; McGill J; Phillips R; Raskin P; Wright JT; Iyengar M; Holeslaw T; Anderson KM;
J Diabetes Complications; 2005; 19(2):74-9. PubMed ID: 15745836
[TBL] [Abstract][Full Text] [Related]
17. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
Feher MD; Henderson AD; Wadsworth J; Poulter C; Gelding S; Richmond W; Sever PS; Elkeles RS
J Hum Hypertens; 1990 Oct; 4(5):571-7. PubMed ID: 1980930
[TBL] [Abstract][Full Text] [Related]
18. Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.
Widmann L; van der Does R; Hörrmann M; Machwirth M
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S143-6. PubMed ID: 1974505
[TBL] [Abstract][Full Text] [Related]
19. [The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus].
Vulpis V; Antonacci A; Prandi P; Bokor D; Pirrelli A
Minerva Med; 1991 Apr; 82(4):189-93. PubMed ID: 1673233
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of native carvedilol in patients with essential hypertension].
Yang T; Zhang Z; Jia Z; Lin S; Peng Y
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(2):153-6. PubMed ID: 11938776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
